Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Dec;66(6):1015–1021. doi: 10.1038/bjc.1992.403

Epidermal growth factor receptor in ovarian tumours: correlation of immunohistochemistry with ligand binding assay.

S C Henzen-Logmans 1, E M Berns 1, J G Klijn 1, M E van der Burg 1, J A Foekens 1
PMCID: PMC1978035  PMID: 1457340

Abstract

Epidermal growth factor receptor (EGFR) was studied in ovarian tumours with immunohistochemical (IH) and ligand-binding assay (LBA). Two different monoclonal antibodies (MoAbs: 2E9, EGFR1) with respect to detecting EGFR with different ligand-binding affinities (low, high and low) were used. When comparing the IH data of MoAbs, 2E9 and EGFR1 a significant correlation was found (2P < 0.0001). Both antibodies stained 77% of the adenocarcinoma samples. The incidence of positivity as well as the mean percentage of stained cells was increased in metastases when compared with primary lesions. In 12.5% overexpression of EGFR (score 3) was noticed in some of the tumour cells. This was not due to amplification of the EGFR gene in any of the 25 ovarian tumours studied (including 6 which showed high expression of EGFR in IH). EGFR was detected in 66% of the adenocarcinomas analysed with LBA. A statistically significant correlation was found between the maximum binding capacities of EGFR obtained from Scatchard plots and the percentage of positive tumour cells determined by MoAb EGFR1 (2P < 0.0001). A weaker correlation was found between the reactivity of MoAb 2E9 and LBA (2P < 0.1). Clinical studies are necessary to determine the possible prognostic impact of EGFR determined with either method, or whether a combination of both will give a better discrimination between high- and low-risk patients.

Full text

PDF
1015

Images in this article

1017Figure 1
on p.1017

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Battaglia F., Scambia G., Benedetti Panici P., Baiocchi G., Perrone L., Iacobelli S., Mancuso S. Epidermal growth factor receptor expression in gynecological malignancies. Gynecol Obstet Invest. 1989;27(1):42–44. doi: 10.1159/000293614. [DOI] [PubMed] [Google Scholar]
  2. Bauknecht T., Birmelin G., Kommoss F. Clinical significance of oncogenes and growth factors in ovarian carcinomas. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):855–862. doi: 10.1016/0960-0760(90)90432-k. [DOI] [PubMed] [Google Scholar]
  3. Bauknecht T., Janz I., Kohler M., Pfleiderer A. Human ovarian carcinomas: correlation of malignancy and survival with the expression of epidermal growth factor receptors (EGF-R) and EGF-like factors (EGF-F). Med Oncol Tumor Pharmacother. 1989;6(2):121–127. doi: 10.1007/BF02985234. [DOI] [PubMed] [Google Scholar]
  4. Bauknecht T., Runge M., Schwall M., Pfleiderer A. Occurrence of epidermal growth factor receptors in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol. 1988 Feb;29(2):147–157. doi: 10.1016/0090-8258(88)90209-0. [DOI] [PubMed] [Google Scholar]
  5. Benraad T. J., Foekens J. A. Hydroxyapatite assay to measure epidermal growth factor receptor in human primary breast tumors. Ann Clin Biochem. 1990 May;27(Pt 3):272–273. doi: 10.1177/000456329002700316. [DOI] [PubMed] [Google Scholar]
  6. Berchuck A., Rodriguez G. C., Kamel A., Dodge R. K., Soper J. T., Clarke-Pearson D. L., Bast R. C., Jr Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 1991 Feb;164(2):669–674. doi: 10.1016/s0002-9378(11)80044-x. [DOI] [PubMed] [Google Scholar]
  7. Damjanov I., Mildner B., Knowles B. B. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest. 1986 Nov;55(5):588–592. [PubMed] [Google Scholar]
  8. Defize L. H., Boonstra J., Meisenhelder J., Kruijer W., Tertoolen L. G., Tilly B. C., Hunter T., van Bergen en Henegouwen P. M., Moolenaar W. H., de Laat S. W. Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol. 1989 Nov;109(5):2495–2507. doi: 10.1083/jcb.109.5.2495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Defize L. H., Moolenaar W. H., van der Saag P. T., de Laat S. W. Dissociation of cellular responses to epidermal growth factor using anti-receptor monoclonal antibodies. EMBO J. 1986 Jun;5(6):1187–1192. doi: 10.1002/j.1460-2075.1986.tb04345.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  11. Gullick W. J., Marsden J. J., Whittle N., Ward B., Bobrow L., Waterfield M. D. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res. 1986 Jan;46(1):285–292. [PubMed] [Google Scholar]
  12. Kienhuis C. B., Heuvel J. J., Ross H. A., Swinkels L. M., Foekens J. A., Benraad T. J. Six methods for direct radioiodination of mouse epidermal growth factor compared: effect of nonequivalence in binding behavior between labeled and unlabeled ligand. Clin Chem. 1991 Oct;37(10 Pt 1):1749–1755. [PubMed] [Google Scholar]
  13. Koenders P. G., Beex L. V., Geurts-Moespot A., Heuvel J. J., Kienhuis C. B., Benraad T. J. Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor-positive human primary breast cancers. Cancer Res. 1991 Sep 1;51(17):4544–4548. [PubMed] [Google Scholar]
  14. Nicholson S., Sainsbury J. R., Halcrow P., Chambers P., Farndon J. R., Harris A. L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet. 1989 Jan 28;1(8631):182–185. doi: 10.1016/s0140-6736(89)91202-6. [DOI] [PubMed] [Google Scholar]
  15. Owens O. J., Stewart C., Brown I., Leake R. E. Epidermal growth factor receptors (EGFR) in human ovarian cancer. Br J Cancer. 1991 Nov;64(5):907–910. doi: 10.1038/bjc.1991.424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rodriguez G. C., Berchuck A., Whitaker R. S., Schlossman D., Clarke-Pearson D. L., Bast R. C., Jr Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol. 1991 Mar;164(3):745–750. doi: 10.1016/0002-9378(91)90508-o. [DOI] [PubMed] [Google Scholar]
  17. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  18. Scheres H. M., De Goeij A. F., Rousch M. J., Hondius G. G., Willebrand D. D., Gijzen A. H., Bosman F. T. Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis. J Clin Pathol. 1988 Jun;41(6):623–632. doi: 10.1136/jcp.41.6.623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Taylor-Papadimitriou J., Shearer M., Stoker M. G. Growth requirements of human mammary epithelial cells in culture. Int J Cancer. 1977 Dec 15;20(6):903–908. doi: 10.1002/ijc.2910200613. [DOI] [PubMed] [Google Scholar]
  20. Zhang X., Silva E., Gershenson D., Hung M. C. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene. 1989 Aug;4(8):985–989. [PubMed] [Google Scholar]
  21. de Bie S. H., Ferreira T. C., Pauwels E. K., Cleton F. J. Immunoscintigraphy for cancer detection: "a thousand ills require a thousand cures". J Cancer Res Clin Oncol. 1992;118(1):1–15. doi: 10.1007/BF01192305. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES